biomarkers

Neurofilament light chain (NfL) — a protein that gets released when nerve cells are damaged — is found at high levels in the blood and cerebrospinal fluid (CSF) of people with multiple sclerosis (MS), suggesting its potential as a biomarker of the disease, a study has found. CSF is…

Intranasal foralumab can modulate a number of immune cell types in people with nonactive secondary progressive multiple sclerosis (SPMS), a study showed, revealing new immune biomarkers that show how the therapy exerts its effects in people with the condition. After three months of treatment, gene activity data showed that…

Certain biomarkers in the cerebrospinal fluid (CSF) — the fluid surrounding the brain and spinal cord — around the time of a multiple sclerosis (MS) diagnosis may help predict the time to reaching certain disability milestones among people with a relapsing-remitting (RRMS) disease course, according to findings from…

Individuals with primary progressive multiple sclerosis (PPMS) have significantly higher concentrations of specific inflammation biomarkers in their spinal fluid than healthy people, an exploratory study shows. For most biomarkers, levels in PPMS patients were comparable to or lower than those seen in people with relapsing-remitting multiple sclerosis (RRMS).

Combining blood and imaging biomarkers might help clinicians better predict cognitive impairment in people with early multiple sclerosis (MS) than using either one alone, a new study suggests. Researchers found that using the two together worked better to predict information processing speed than did either blood or MRI biomarkers…

Rune Labs has partnered with Coastal Research Institute (CRI) to identify new and noninvasive biomarkers of the loss of myelin, the fatty sheath surrounding nerve fibers that is progressively damaged by multiple sclerosis (MS). The collaboration involves a patient study that will take advantage of Rune Labs’…

Simoa, a technology that detects relevant molecules in samples with up to 1,000 times greater sensitivity than conventional methods, has helped to advance research into a blood biomarker expected to predict future disease activity in multiple sclerosis (MS) patients. Specifically, Quanterix‘s ultra-sensitive technology allowed an international team…

A measure of the nose’s sensitivity to smell could be used to detect whether treatments for relapsing multiple sclerosis (MS) are working or not, a new study indicates. The scientists noted that their results need to be validated through further study, but said the findings suggest that a smell…

A neurology professor at the University of Pennsylvania (UPenn) has received the 2021 Barancik Prize for Innovation in MS Research for his work in understanding how the immune system causes multiple sclerosis (MS). The international $100,000 prize, administered by the National MS Society, was awarded to Amit…

Numares has signed an exclusive licensing agreement with Oxford University Innovation to develop and commercialize a panel of biomarkers that identify disease progression in people with multiple sclerosis (MS). Specifically, the company aims to create a tool that detects early signs of conversion from relapsing remitting…

In people with early-stage multiple sclerosis (MS), the presence of high levels of neurofilament light chain (sNfL) protein in the bloodstream combined with thinning of the retina is a strong indicator of future disease activity, a recent study demonstrates. “Our findings encourage the application of both sNfL and retinal…

A nurse and PhD candidate with multiple sclerosis (MS) is looking for disease biomarkers that can help healthcare providers better estimate how individual cases of MS will progress. The goal of Stephanie Buxhoeveden’s research, now supported by a grant from the American Association of Nurse Practitioners (AANP), is…

Retinal Layer Thickness May Predict MS Progression, Relapses We all know how unpredictable MS is. For some, it progresses very quickly, while for others, it follows a slow progression over many years. Wouldn’t it be nice if we knew the course our disease is likely to follow, right from…

Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25–27. Go here to see the latest stories from the conference. While researchers make progress in pinpointing markers of disease progression in multiple sclerosis (MS), identifying those that signal…

An antibody analysis has identified two biomarkers that can be used to predict the development of multiple sclerosis (MS) in people with optic neuritis, a study reports.  Further research is, however, required to validate these findings…

CXCL13, an inflammatory biomarker, may be a good marker of likely future disease activity in people with multiple sclerosis (MS), a study suggests. The study, “Intrathecally produced CXCL13: A predictive biomarker in multiple sclerosis,” was published in the Multiple Sclerosis Journal – Experimental, Translational and Clinical. Clinicians caring…

The development of a diagnostic test using neurofilament light chain (NfL) — a biomarker for nerve cell damage — for people with multiple sclerosis (MS) will be part of a collaboration program between Siemens Healthineers and Novartis. The goal of this new collaboration is to design, develop,…

The upcoming MSVirtual2020 meeting, the largest international conference dedicated to multiple sclerosis (MS) research, will focus on advances and breakthroughs made in MS causes and risk factors, diagnostic tools, treatment response biomarkers, technology, and therapies and interventions. The 8th joint meeting of the Americas Committee for Treatment and…

Australian scientists have discovered subsets of immune cells that differ between people who have multiple sclerosis (MS) and those who don’t. Because the prevalence of these cells correlates with autoimmune attacks, they represent potential targets for MS therapies. The study, “IgG3 + B…

People with progressive forms of multiple sclerosis (MS) have faster and disease-modifying therapy (DMT)-resistant retinal atrophy (thinning), compared to those with relapsing-remitting MS (RRMS), a study shows. Data also highlighted that the thickness of deeper layers of the retina could be used as potential biomarkers of neurodegeneration in…

Altered levels of molecules important for cell regulation — called microRNAs — have been found in specific immune cells isolated from the blood of people with multiple sclerosis (MS), a study reveals. These immune cells, called monocytes, transform into macrophage cells,…

Harvard professor and scientist Francisco Quintana, PhD, has been awarded the 2019 Barancik Prize for Innovation in MS Research for his work in understanding what causes multiple sclerosis (MS), and how to stop its development. Quintana has developed innovative research programs that use cutting-edge technology to help…

Siemens Healthineers has signed a license and supply agreement with Quanterix that helps it in developing blood tests for neurofilament light chain (NfL) to aid in early disease detection, evidence of progression, and measuring treatment response in people with neurological disorders such as multiple sclerosis (MS). Siemens Healthineers…

A new public-private initiative brings academic and industry researchers from 15 European countries together in a large-scale effort to understand differences and commonalities in seven immune-mediated and inflammatory diseases, including multiple sclerosis, so to better predict a patient’s likely response to treatment and likely disease progression. The project, called 3TR…

Higher Intellectual Ability, Early-life Physical Activity May Protect Against Cognitive Impairment in MS, Study Suggests The finding that physical activity provides a protective effect for cognitive abilities makes sense to me. I recently listened to a webinar discussing brain atrophy, which has a direct relationship with cognitive impairment, and…

The levels of neurofilament light chain (NfL) and chitinase3-like1 (CHI3L1) in the cerebrospinal fluid — the liquid that surrounds the brain and spinal cord — serve as respective biomarkers of disease activity and progression in multiple sclerosis (MS), a study reports. Measuring levels of both proteins also helps to…

The National Multiple Sclerosis Society awarded more than $339,000 to Clene Nanomedicine to support clinical tests into its lead candidate CNM-Au8 in treating multiple sclerosis (MS) by protecting nerve cells and restoring myelin. The grant was awarded under the National MS Society’s Fast Forward program, which aims…

Patients with progressive multiple sclerosis (MS) have higher levels of protein markers of activated glial cells than those with relapsing-remitting MS (RRMS) or patients with other neurological disorders, according to a new study. The findings also indicated that scoring the extent of glial involvement in relation to nerve…

Scientists at the University of Huddersfield, U.K., are trying to develop a breath test to detect volatile molecules exhaled only by people with multiple sclerosis (MS). Doing so might offer a non-invasive and simple way to diagnose the disease. The research team now plans to undertake…

#AANAM – Biogen Offers Update on Development Plans for MS Therapies The pharma company that brought you Tysabri (natalizumab) is investigating a new process for treating multiple sclerosis. The treatment looks for something called neurofilament light chain (NfL), a potential biomarker that’s released from damaged neurons.